All In Biotech

Drug Trial Radar · NCT01731431

Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes

Last checked: Nov 20, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 914 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

914

Actual

Start

May 18, 2012

Primary completion

Mar 15, 2017

Study completion Jun 2, 2017

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
URC-CIC Paris Descartes Necker Cochin
First posted
Nov 21, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial aims to test whether glibenclamide is non-inferior to insulin for the treatment of gestational diabetes.

Conditions

  • Diabetes
  • Gestational

Interventions

  • InsulinOther

  • GlyburideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemiaTime frame: At birth until neonatal discharge from maternity

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Marie-Victoire Senat

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.